bluebird bio Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : bluebird bio Inc.

BLUE 4.970

0.0%

Jun 2 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Biotech Jim	3/6/2014 9:13:32 AM
	of 163

Two pieces of news on the bluebird front... Report last evening from BLUE on 2013 highlights and pipeline update (OT for BLUE) I have been working with another local Audubon member on cutting out bluebird houses to put up in the local area, this past week we made 12 house kits, and went to a charter school to work with 6th-8th graders to put them together. Trying to get young kids aware of natural resources, conservation, and sustainability. Will make some 30 or so kits overall, then we will focus on wood duck houses... Here is the link to the BLUE report: investor.bluebirdbio.com Pipe update from the PR: Lenti-D (Childhood Cerebral Adrenoleukodystrophy) Starbeam Study: In October 2013, the first patient in the phase 2/3 Starbeam (ALD-102) study was transplanted with bluebird’s Lenti-D product candidate. This study is planned to enroll 15 patients with childhood cerebral adrenoleukodystrophy with at least 12 patients being evaluable. The primary endpoint of the study is the percentage of patients that do not develop a major functional disability at 24 months after their transplant. We anticipate completing enrollment in 2015.LentiGlobin (beta Thalassemia and Sickle Cell Disease) HGB-205 Study: In November 2013, the first patient in the phase 1/2 HGB-205 study was transplanted with bluebird’s LentiGlobin product candidate. The HGB-205 study is planned to enroll 7 patients with beta thalassemia major or sickle cell disease at a single site in Paris, France. We anticipate that the first sickle cell patient will be transplanted in this study in 2014.Northstar Study: The Northstar (HGB-204) study is a US phase 1/2 study that is planned to enroll 15 patients with thalassemia major. The first patient in this study is expected to be transplanted in early 2014.bluebird bio plans to present preliminary data from the HGB-205 and Northstar studies in late 2014.Sickle Cell Disease Study: bluebird bio anticipates filing an IND in mid-2014 to start a study with LentiGlobin in patients with sickle cell disease.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next